Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$58.00 -0.5%	$57.33	$52.93 ▼ $94.85	$11.14B	0.18	1.94 million shs	1.48 million shs
CCXI ChemoCentryx	$51.99	$51.95	$14.95 ▼ $52.00	$3.71B	1.22	1.68 million shs	113 shs
INCY Incyte	$86.16 +0.4%	$71.17	$53.56 ▼ $86.50	$16.83B	0.71	1.88 million shs	1.84 million shs
UTHR United Therapeutics	$312.06 +0.8%	$295.40	$266.98 ▼ $417.82	$14.08B	0.57	521,393 shs	586,994 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+2.53%	-3.91%	+0.12%	+0.05%	-35.92%
CCXI ChemoCentryx	0.00%	0.00%	0.00%	0.00%	0.00%
INCY Incyte	+5.20%	+10.56%	+22.68%	+36.79%	+38.42%
UTHR United Therapeutics	+2.76%	+2.42%	+4.04%	+1.91%	-4.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMRN BioMarin Pharmaceutical	4.9979 of 5 stars	4.4	5.0	0.0	3.3	3.9	2.5	4.4
CCXI ChemoCentryx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INCY Incyte	4.5886 of 5 stars	2.2	2.0	0.0	2.8	2.8	3.3	4.4
UTHR United Therapeutics	4.9347 of 5 stars	3.3	4.0	0.0	4.6	4.2	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$93.17	60.64% Upside
CCXI ChemoCentryx	0.00	N/A	N/A	N/A
INCY Incyte	2.33	Hold	$81.20	-5.76% Downside
UTHR United Therapeutics	2.69	Moderate Buy	$382.00	22.41% Upside

Current Analyst Ratings Breakdown

Latest CCXI, UTHR, BMRN, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
8/13/2025	UTHR United Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$385.00 ➝ $415.00
8/6/2025	BMRN BioMarin Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$101.00 ➝ $106.00
8/6/2025	INCY Incyte	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$67.00 ➝ $89.00
8/5/2025	BMRN BioMarin Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$94.00
8/5/2025	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$113.00 ➝ $114.00
8/1/2025	INCY Incyte	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$90.00
7/31/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$425.00 ➝ $400.00
7/31/2025	UTHR United Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$314.00 ➝ $295.00
7/30/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$88.00 ➝ $103.00
7/30/2025	INCY Incyte	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform	$52.00 ➝ $60.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$2.85B	3.90	$3.31 per share	17.52	$31.39 per share	1.85
CCXI ChemoCentryx	$32.22M	115.14	N/A	N/A	$4.09 per share	12.71
INCY Incyte	$4.24B	3.97	$0.58 per share	147.42	$21.36 per share	4.03
UTHR United Therapeutics	$2.88B	4.89	$29.41 per share	10.61	$159.04 per share	1.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$426.86M	$3.37	17.21	13.30	0.73	21.45%	12.59%	10.13%	N/A
CCXI ChemoCentryx	-$131.76M	-$1.89	N/A	N/A	N/A	-357.01%	-48.52%	-30.59%	N/A
INCY Incyte	$32.62M	$4.40	19.58	13.17	0.64	18.99%	21.99%	14.43%	N/A
UTHR United Therapeutics	$1.20B	$25.62	12.18	11.35	4.57	40.36%	18.73%	16.49%	10/29/2025 (Estimated)

Latest CCXI, UTHR, BMRN, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.80	$6.41	-$0.39	$6.41	$802.13 million	$798.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
CCXI ChemoCentryx	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.10	5.56	3.60
CCXI ChemoCentryx	0.02	4.54	4.47
INCY Incyte	0.01	2.85	2.78
UTHR United Therapeutics	N/A	7.26	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
CCXI ChemoCentryx	81.09%
INCY Incyte	96.97%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.85%
CCXI ChemoCentryx	8.30%
INCY Incyte	17.80%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,040	192.01 million	190.38 million	Optionable
CCXI ChemoCentryx	178	71.36 million	65.43 million	Optionable
INCY Incyte	2,617	195.28 million	160.52 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

CCXI, UTHR, BMRN, and INCY Headlines

Recent News About These Companies

Nuveen LLC Acquires Shares of 270,975 United Therapeutics Corporation (NASDAQ:UTHR)

August 14 at 5:15 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Increases Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

August 14 at 4:32 AM | marketbeat.com

Citigroup Inc. Lowers Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

August 14 at 4:24 AM | marketbeat.com

Deutsche Bank AG Cuts Stake in United Therapeutics Corporation (NASDAQ:UTHR)

August 14 at 3:49 AM | marketbeat.com

United Therapeutics price target raised to $415 from $385 at UBS

August 13 at 11:58 AM | msn.com

5 Insightful Analyst Questions From United Therapeutics’s Q2 Earnings Call

August 13 at 6:57 AM | finance.yahoo.com

UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty

August 13 at 6:57 AM | finance.yahoo.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by Charles Schwab Investment Management Inc.

August 13 at 3:43 AM | marketbeat.com

Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle

August 12 at 4:08 PM | msn.com

United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis

August 12 at 12:10 PM | tipranks.com

Liquidia Corporation Reports Strong Early Adoption of YUTREPIA™ with Over 900 Patient Prescriptions and Positive Interim Data from ASCENT Trial

August 12 at 7:07 AM | quiverquant.comQ

Vanguard Group Inc. Increases Position in United Therapeutics Corporation (NASDAQ:UTHR)

August 12 at 4:04 AM | marketbeat.com

PNC Financial Services Group Inc. Grows Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

August 12 at 3:45 AM | marketbeat.com

XTX Topco Ltd Invests $313,000 in United Therapeutics Corporation (NASDAQ:UTHR)

August 12 at 3:27 AM | marketbeat.com

LPL Financial LLC Has $7.78 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

August 12 at 3:26 AM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Rating of "Moderate Buy" by Brokerages

August 12 at 2:59 AM | marketbeat.com

ASR Vermogensbeheer N.V. Invests $378,000 in United Therapeutics Corporation (NASDAQ:UTHR)

August 11 at 4:07 AM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares

August 10, 2025 | marketbeat.com

New Age Alpha Advisors LLC Purchases 4,525 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

August 8, 2025 | marketbeat.com

977 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Purchased by Arkadios Wealth Advisors

August 7, 2025 | marketbeat.com

Federated Hermes Inc. Reduces Position in United Therapeutics Corporation (NASDAQ:UTHR)

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCXI, UTHR, BMRN, and INCY Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$58.00 -0.30 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$58.06 +0.06 (+0.11%)

As of 06:22 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Incyte NASDAQ:INCY

$86.16 +0.31 (+0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$86.16 0.00 (0.00%)

As of 06:11 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

United Therapeutics NASDAQ:UTHR

$312.06 +2.34 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$310.10 -1.96 (-0.63%)

As of 05:09 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time